Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
March 10, 2025 3:25 PM EDT
Jones Trading analyst Catherine Novack reiterated a Buy rating and $20.00 price target on WAVE Life Sciences (NASDAQ: WVE)
The analyst comments "What's new: We saw the first gene editing in AATD from Beam Therapeutics (BEAM, Roy, Buy, $34 PT) (press release). Initial results look positive, and it's... More
March 10, 2025 12:59 PM EDT
Jones Trading analyst Soumit Roy upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Hold to Buy with a price target of $34.00.
The analyst comments "Model changes: We are raising our POS for AATD to 35% from 15%, increasing our adjusted peak sales to ~$1.9BN in 2036, upgrading our rating to Buy from Hold and a PT of $34. BEAM's in vivo edited AATD data mark an important step for the gene editing space, where effective editing levels were observed. Liver biopsy data in the future would accurately quantify the percent editing, but management mentioned that likely >50%... More
